[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Abstract

Context.  —Elevated plasma homocysteine is a known risk factor for atherosclerotic vascular disease, but the strength of the relationship and the interaction of plasma homocysteine with other risk factors are unclear.

Objective.  —To establish the magnitude of the vascular disease risk associated with an increased plasma homocysteine level and to examine interaction effects between elevated plasma homocysteine level and conventional risk factors.

Design.  —Case-control study.

Setting.  —Nineteen centers in 9 European countries.

Patients.  —A total of 750 cases of atherosclerotic vascular disease (cardiac, cerebral, and peripheral) and 800 controls of both sexes younger than 60 years.

Measurements.  —Plasma total homocysteine was measured while subjects were fasting and after a standardized methionine-loading test, which involves the administration of 100 mg of methionine per kilogram and stresses the metabolic pathway responsible for the irreversible degradation of homocysteine. Plasma cobalamin, pyridoxal 5'-phosphate, red blood cell folate, serum cholesterol, smoking, and blood pressure were also measured.

Results.  —The relative risk for vascular disease in the top fifth compared with the bottom four fifths of the control fasting total homocysteine distribution was 2.2 (95% confidence interval, 1.6-2.9). Methionine loading identified an additional 27% of atrisk cases. A dose-response effect was noted between total homocysteine level and risk. The risk was similar to and independent of that of other risk factors, but interaction effects were noted between homocysteine and these risk factors; for both sexes combined, an increased fasting homocysteine level showed a more than multiplicative effect on risk in smokers and in hypertensive subjects. Red blood cell folate, cobalamin, and pyridoxal phosphate, all of which modulate homocysteine metabolism, were inversely related to total homocysteine levels. Compared with nonusers of vitamin supplements, the small number of subjects taking such vitamins appeared to have a substantially lower risk of vascular disease, a proportion of which was attributable to lower plasma homocysteine levels.

Conclusions.  —An increased plasma total homocysteine level confers an independent risk of vascular disease similar to that of smoking or hyperlipidemia. It powerfully increases the risk associated with smoking and hypertension. It is time to undertake randomized controlled trials of the effect of vitamins that reduce plasma homocysteine levels on vascular disease risk.

References
1.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes . JAMA . 1995;274:1049-1057.Article
2.
Ueland PM, Refsum H, Brattström L.  Plasma homocysteine and vascular disease . In: Francis RB Jr, ed. Atherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function . New York, NY: Marcel Dekker Inc; 1992:183-236.
3.
Graham IM.  Homocysteine as a risk factor for cardiovascular disease . Trends Cardiovasc Med . 1991;1:244-249.Article
4.
McCully KS, Wilson RB.  Homocysteine theory of arteriosclerosis . Atherosclerosis . 1975;22:215-227.Article
5.
McCully KS.  Homocysteine theory of arteriosclerosis: development and current status . Atheroscler Rev . 1983;11:157-246.
6.
Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G.  Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults: the Atherosclerosis Risk in Communities Study . Circulation . 1993;87:1107-1113.Article
7.
Mayer E, Miller D, Gupta A, et al.  High homocysteine concentrations: an independent risk factor for coronary atherosclerosis in women . J Am Coll Cardiol . 1995;25:390A. Abstract 802-5.Article
8.
Sheahan R, Graham I, Refsum H, et al.  Women with coronary artery disease: lower folate and higher homocysteine . Eur Heart J . 1994;15:530.Article
9.
Mudd SH, Levy HL, Skovby F.  Disorders of transsulphuration . In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease . 6th ed. New York, NY: McGraw Hill International Book Co; 1989;1:693-734.
10.
Cooper BA, Rosenblatt DS.  Inherited defects of vitamin B12 metabolism . Annu Rev Nutr . 1987; 7:291-320.Article
11.
Rosenblatt DS, Cooper BA.  Inherited disorders of vitamin B12 utilization . Bioessays . 1990;12:231-334.Article
12.
Ubbink JB, Vermaals WJH, van der Merwe A, Becker PJ.  Vitamin B-12, vitamin B-6 and folate nutritional status in men with hyperhomocysteinemia . Am J Clin Nutr . 1993;57:47-53.
13.
Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L.  Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid . J Intern Med . 1995;237:381-388.Article
14.
Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B.  Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects . J Intern Med . 1994;236:633-641.Article
15.
Witteman JCM, Uiterwaal C.  Study design to examine interactions between heterozygous homocystinuria and other risk factors for vascular disease . In: Robinson K, ed. Homocysteinemia and Vascular Disease: Proceedings of an EC Comae-Epidemiology Expert Group Workshop . Luxembourg, Belgium: Commission of the European Communities; 1990:119-130. Report No. E U R12834 EN.
16.
Graham I. Homocysteinemia and Vascular Disease: Annual Report for 1989-90: Methodology and Protocol for an International Case-Control Study . Luxembourg, Belgium: Commission of the European Communities; 1992. Report No. EUR 13927 EN.
17.
Lindgren A, Brattström L, Norrving B, Hultberg B, Andersson A, Johansson B.  Plasma homocysteine in the acute and convalescent phases after stroke . Stroke . 1995;26:795-800.Article
18.
Boers G.  Refinement of the methionine loading test . In: Robinson K, ed. Homocysteinemia and Vascular Disease: Proceedings of an EC Comae-Epidemiology Expert Group Workshop . Luxembourg, Belgium: Commission of the European Communities; 1990:61-66.
19.
Refsum H, Ueland PM, Svardal AM.  Fully automated fluorescence assay for determining total homocysteine in plasma . Clin Chem . 1989;35:1921-1927.
20.
Rothman KJ. Modern Epidemiology . Boston, Mass: Little Brown & Co; 1986.
21.
Lee J.  An insight on the use of multiple logistic regression analysis to estimate association between risk factor and disease occurrence . Int J Epidemiol . 1986;15:22-29.Article
22.
Silberberg JA.  Estimating the benefits of cholesterol lowering: are risk factors for coronary heart disease multiplicative? J Clin Epidemiol . 1990;43:875-879.Article
23.
SAS Institute Inc. SAS Technical Report P-229 SAS/STATSoftware: Changes and Enhancements, Version 6.07. Cary, NC: SAS Institute Inc; 1992.
24.
Brattström L, Israelsson B, Norrving B, et al.  Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment . Atherosclerosis . 1990;81:51-60.Article
25.
Brattström L, Israelsson B, Hultberg B.  Plasma homocysteine and methionine tolerance in earlyonset vascular disease . Haemostasis . 1989;19( (suppl 1) ):35-44.
26.
Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J.  Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI family heart study . Atherosclerosis . 1995;116:147-151.Article
27.
Stampfer MJ, Malinow MR, Willett WC, et al.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians . JAMA . 1992;268:877-881.Article
28.
Taylor LM, DeFrang RD, Harris EJ, Porter JM.  The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease . J Vase Surg . 1991;13:128-136.Article
29.
Arnesen E, Refsum H, Bonaa K, Ueland PM, Forde OH, Nordrehaug JE.  Serum total homocysteine and coronary heart disease . Int J Epidemiol . 1995;24:704-709.Article
30.
Selhub J, Jacques PF, Bostom AG, et al.  Association between plasma homocysteine concentrations and extracranial carotid artery stenosis . N Engl J Med . 1995;332:286-291.Article
31.
Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men . Lancet . 1995;346:1395-1398.Article
32.
Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ.  A prospective study of plasma homocyst(e)ine and risk of ischemic stroke . Stroke . 1994;25:1924-1930.Article
33.
Alfthan G, Pekkanen J, Jauhianen M, et al.  Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study . Atherosclerosis . 1994;106:9-19.Article
34.
Pancharuniti N, Lewis CA, Sanberlich HE, et al.  Plasma homocysteine, folate and vitamin B-12 concentrations and risk for early onset coronary artery disease . Am J Clin Nutr . 1994;59:940-948.
35.
Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg I.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population . JAMA . 1993;270:2693-2698.Article
36.
Olszewski AJ, McCully K.  Homocysteine metabolism and the oxidative modification of proteins and lipids . Free Radic Biol Med . 1993;14:683-693.Article
37.
Parthasarathy S.  Oxidation of low density lipoproteins by thiol compounds leads to its recognition by the acetyl LDL receptor . Biochim Biophys Acta . 1987;917:337-340.Article
38.
Nygard O, Vollset SE, Refsum H, et al.  Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study . JAMA . 1995;274:1526-1533.Article
×